NCT02075021View on ClinicalTrials.gov

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

Lenalidomide

DRUG

nab-paclitaxel

Trial Locations (1)

10016

NYU School of Medicine, New York

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

NYU Langone Health

OTHER